Evidence map›Paper›PMID 36128585›Full record

ArticleNeuro-oncology advances

Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis.

Rituraj Upadhyay, Swapnil Khose, Halyna Pokhylevych, Arnold C Paulino, Mary Frances McAleer, Amol Ghia, Jing Li, Debra Nana Yeboa, Monica Loghin, Rebecca Harrison and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Rituraj UpadhyayDepartment of Radiation Oncology, The James Cancer Centre, Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-4079-1268
Swapnil KhoseDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Halyna PokhylevychDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Arnold C PaulinoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-0269-3045
Mary Frances McAleerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amol GhiaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jing LiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Debra Nana YeboaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Monica LoghinDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rebecca HarrisonDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Barbara O'BrienDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
John De GrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Vinay K PuduvalliDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Claudio TatsuiDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher Alvarez-BreckenridgeDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sujit PrabhuDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Larry RhinesDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wafik ZakyDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Frank LinTexas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Jeffery S WeinbergDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gregory FullerDepartment of Neuro-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (G.F.).
David I SandbergDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jason Michael JohnsonDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Susan L McGovernDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5286-0649

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Background: Primary spinal high-grade gliomas (S-HGG) are rare aggressive tumors; radiation therapy (RT) often plays a dominant role in management. We conducted a single-institution retrospective review to study the clinicopathological features and management of S-HGGs. Methods: Patients with biopsy-proven S-HGG who received RT from 2001 to 2020 were analyzed for patient, tumor, and treatment characteristics. Kaplan-Meier estimates were used for survival analyses. Results: Twenty-nine patients were identified with a median age of 25.9 years (range 1-74 y). Four patients had GTR while 25 underwent subtotal resection or biopsy. All patients were IDH wildtype and MGMT-promoter unmethylated, where available. H3K27M mutation was present in 5 out of 10 patients tested, while one patient harbored p53 mutation. Median RT dose was 50.4 Gy (range 39.6-54 Gy) and 65% received concurrent chemotherapy, most commonly temozolomide. Twenty-three (79%) of patients had documented recurrence. Overall, 16 patients relapsed locally, 10 relapsed in the brain and 8 developed leptomeningeal disease; only 8 had isolated local relapse. Median OS from diagnosis was 21.3 months and median PFS was 9.7 months. On univariate analysis, age, gender, GTR, grade, RT modality, RT dose and concurrent chemotherapy did not predict for survival. Patients with H3K27M mutation had a poorer PFS compared to those without mutation (10.1 m vs 45.1 m) but the difference did not reach statistical significance ( Conclusions: The prognosis of patients with spinal HGGs remains poor with two-thirds of the patients developing distant recurrence despite chemoradiation. Survival outcomes were similar in patients ≤ 29 years compared to adults > 29 years. A better understanding of the molecular drivers of spinal HGGs is needed to develop more effective treatment options.

Indexed as

high-grade gliomaproton therapyradiationspinal glioma

Identifiers

PMID36128585
PMCPMC9476222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.